Results 61 to 70 of about 12,862 (201)

Metastasis of Hepatocellular Carcinoma to the Urinary Bladder: A Case Report and Literature Review

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction Although secondary bladder tumors from distant metastases are rare, those originating from hepatocellular carcinoma are particularly uncommon, with only a few cases reported to date. Case Presentation An 81 year old male with hepatocellular carcinoma developed a rapidly growing 23 mm‐sized bladder tumor during systemic therapy ...
Eri Fukagawa, Suguru Oka, Kazushige Sakaguchi, Shigeki Yamamoto, Masako Ikemura, Norio Akuta, Shinji Urakami   +6 more
wiley   +1 more source

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia

, 2023
Introduction. Direct-acting antivirals (DAAs) has been developed for treatment hepatitis C virus (HCV). Therapy of HCV using DAA has shown high sustained virologic response (SVR) and shortening duration of therapy.
Yayah Nugroho, Irsan Hasan, Budiman Sujatmika Sulaiman, Gita Aprilicia, Nunuk Tri Wahyuni, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan   +7 more
core   +1 more source

Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose

Gut and Liver, 2020
Background/Aims: Sofosbuvir (SOF)-based therapy has been used in Korean patients with chronic hepatitis C virus (HCV) infection since January 2016. This study aimed to investigate the real-life effectiveness and safety of SOF-based therapy in genotype 2 ...
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong   +7 more
doaj   +1 more source

Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT To assess the sustained virologic response (SVR12) and safety profile of 12‐week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)‐infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis ...
Lu Yan, Maimaitijiang Wubuliaishan, Xiaoni Kou, Maimaitiaili Tuerxun, Mingbo Yang, Fanpu Ji, Yingli He, Jiuping Wang, Longdong Zhu, Xiaohong Gao, Fuchun Jing, Xiangchun Ding, Hong Du, Ye Zhang, Hong Jiang   +14 more
wiley   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

, 2017
BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We
Bansal, Meena B, Michael P. Manns, Stephen Pianko, Younes, Ziad, Mchutchison, John, G., Landis, Charles, S, Natarajan Ravendhran, Robert H. Hyland, Flamm, Steven L, Cooper, Curtis, Younes, Ziad H, Tran, Tram, Curry, Michael, Tran, Tram T, Manns, Michael, Huang, K.C., Huang, K C, Reddy, K R, Schiff, Eugene, Curtis L. Cooper, Jie Zhang, Brainard, Diana M, Simone I. Strasser, Michael P. Curry, Steven L. Flamm, Pianko, Stephen, Svarovskaia, Evguenia, Charles S. Landis, Peter Buggisch, Buggisch, Peter, Diana M. Brainard, G. Mani Subramanian, Stamm, Luisa, Stuart C. Gordon, Marc Bourlière, Zhang, Jie, Flamm, Steven, L., Kowdley, Kris, V., John G. McHutchison, Bourlière, Marc, Ravendhran, Natarajan, Hadas Dvory-Sobol, Curry, Michael P, Stefan Zeuzem, Luisa M. Stamm, Brainard, Diana, K. Rajender Reddy, Tram T. Tran, Eugene R. Schiff, Alnoor Ramji, Evguenia Svarovskaia, McHutchison, John G, Vierling, John, Ramji, Alnoor, Reddy, K. Rajender, Subramanian, G. Mani, Kris V. Kowdley, Subramanian, G M, Cooper, Curtis L, Dvory-Sobol, Hadas, Hyland, Robert, John M. Vierling, Huang, K.C, Verna, Elizabeth C, Strasser, Simone I, Bansal, Meena, Victor de Lédinghen, K.C. Huang, de Lédinghen, Victor, Landis, Charles S, Elizabeth C. Verna, Subramanian, G Mani, Hyland, Robert H, Stamm, Luisa M, Gordon, Stuart, Myron Tong, Meena B. Bansal, Ziad H. Younes, Kowdley, Kris V, Reddy, K Rajender, Gordon, Stuart C, Strasser, Simone, Verna, Elizabeth, Manns, Michael P, Tong, Myron, Schiff, Eugene R, Vierling, John M, Zeuzem, Stefan   +87 more
core   +1 more source

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients

Canadian Journal of Gastroenterology and Hepatology, 2016
Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence ...
A. Ajlan, A. Al-Jedai, H. Elsiesy, D. Alkortas, W. Al-Hamoudi, R. Alarieh, M. Al-Sebayel, D. Broering, F. Aba Alkhail   +8 more
doaj   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source